Phaseline

Companies › Shanghai Longwood Biopharmaceuticals

Shanghai Longwood Biopharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Infectious disease, Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LW402–Phase 3Moderate to Severe Atopic DermatitisMar 2028
LW231–Phase 1Chronic HBV InfectionMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07179575LW231Phase 1Chronic HBV InfectionInfectious diseaseMar 2027
NCT07370909LW402Phase 3Moderate to Severe Atopic DermatitisImmunologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

IR INNOVATE RESEARCH PRIVATE Institut Pasteur Prime Gene Therapeutics Hangzhou Highlightll Pharmaceutical Paradigm Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.